Czechia· CZ-0230571
FEIBA
A faktor viii-inhibitor bypass aktivität - feiba product containing antiinhibitory coagulation factor complex, registered in Czechia by Baxalta Innovations GmbH, Vídeň. The same ATC class is registered in 10 of our 19 countries.
Checked against SÚKL (Czech Republic) on
Informational only — not a medical device.
Where it is registered
Faktor viii-inhibitor bypass aktivität - feiba is registered in 10 of 19 countries.
Countries holding a registration under ATC B02BD03 (faktor viii-inhibitor bypass aktivität - feiba), each read from that country’s own register.
- This record: Czechia, from SÚKL (Czech Republic)
- 6 of them publish a price we can compare per daily dose
Faktor viii-inhibitor bypass aktivität - feiba · ATC B02BD03
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
SÚKL (Czech Republic)- Active substance
- ANTIINHIBITORY COAGULATION FACTOR COMPLEX
- Manufacturer
- Baxalta Innovations GmbH, Vídeň
- Country
- Czechia (CZ)
- ATC code
- B02BD03
- ATC class
- Faktor VIII-Inhibitor Bypass Aktivität - FEIBA
- Defined daily dose
- 7 TSD, E
- Reimbursed
- Not published by this register
- Source register
- SÚKL (Czech Republic)
- Last checked
- September 28, 2026
Packs & prices · 1
1 priced- cz_kod_sukl02305711X500U+10ML+BAXJECTCZK 11349.91
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
5 interactions on record for faktor viii-inhibitor bypass aktivität - feiba.
Graded by severity as the source publishes them — 4 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Faktor viii-inhibitor bypass aktivität - feiba · interactions on record
5 records
- 4 severe
- 1 moderate
Most severe, free to view
- Aminocaproic acidB02AA01severe
- Tranexamic acidB02AA02severe
- AprotininB02AB01severe
- EmicizumabB02BX06severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under B02BD03
Faktor viii-inhibitor bypass aktivität - feiba, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of SÚKL (Czech Republic). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dda2edad-583b-4b86-9fe8-7a0029bd4395 GET /v1/drugs/dda2edad-583b-4b86-9fe8-7a0029bd4395?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "INF PSO LQF",
"source": "sukl",
"strength": "50U/ML",
"pack_size": "1X500U+10ML+BAXJECT",
"substance": "ANTIINHIBITORY COAGULATION FACTOR COMPLEX",
"cz_kod_sukl": "0230571",
"product_type": "KR/O",
"substance_codes": "16820",
"registration_state": "R",
"registration_number": "75/133/80-B/C"
}See everything about faktor viii-inhibitor bypass aktivität - feiba.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.